Trial Profile
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs UB 311 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors United Neuroscience
- 10 Aug 2023 According to Vaxxinity, Inc. media release, data from this study published in The Lancets eBioMedicine (Volume 94, 104665, August 2023)
- 10 Aug 2023 Results published in the Vaxxinity, Inc Media Release
- 21 Jan 2019 Status changed from active, no longer recruiting to completed.